A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.

被引：0
|
作者：
Kilari, Deepak
Szabo, Aniko
Hall, William A.
Nelson, Ariel Ann
Johnson, Scott
Giever, Thomas A.
Burfeind, John
Tolat, Parag
Bylow, Kathryn A.
Iczkowski, Kenneth
Sun, Yunguang
Rui, Hallgeir
Thomas, James P.
Nevalainen, Marja
机构：
[1] Med Coll Wisconsin, Froedtert Canc Ctr, Dept Med, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS220
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
    Harari, Sergio
    Elia, Davide
    Caminati, Antonella
    Geginat, Jens
    Luisi, Francesca
    Pelosi, Giuseppe
    Specchia, Claudia
    Torre, Olga
    Trevisan, Roberta
    Vasco, Chiara
    Zompatori, Maurizio
    Cassandro, Roberto
    LANCET RESPIRATORY MEDICINE, 2024, 12 (12): : 967 - 974
  • [2] A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.
    Tran, Ben
    Courtney, Kevin Dale
    Sokolova, Alexandra
    Horvath, Lisa
    Danila, Daniel Costin
    Hawley, Jessica E.
    Pook, David William
    Brown, Landon Carter
    Whang, Young E.
    Buetikofer, Simon
    Wang, Kejia
    Zorko, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS435 - TPS435
  • [3] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [4] Anlotinib plus pemetrexed as a further treatment for patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.
    Chen, Jueming
    Wei, Wei
    Zheng, Lie
    Li, Han
    Feng, Yanling
    Wan, Ting
    Qiu, Jiaqi
    Jiang, Xingyu
    Xiong, Ying
    Zheng, Min
    Li, Jundong
    Huang, He
    Song, Libing
    Liu, Jihong
    Zhang, Yanna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
    Schwartzberg, Lee
    Hermann, Robert
    Flinn, Ian
    Flora, Douglas
    Hsi, Eric D.
    Hamid, Oday
    Shi, Peipei
    Lin, Boris K.
    Myrand, Scott P.
    Nguyen, Tuan S.
    Dreyling, Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (01) : 91 - 97
  • [6] Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufi K.
    Perabo, Frank
    De Phung
    Hirmand, Mohammad
    Smith, Matthew R.
    LANCET ONCOLOGY, 2014, 15 (06): : 592 - 600
  • [7] An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
    Andrea Necchi
    Salvatore Lo Vullo
    Luigi Mariani
    Daniele Raggi
    Patrizia Giannatempo
    Giuseppina Calareso
    Elena Togliardi
    Flavio Crippa
    Nicola Di Genova
    Federica Perrone
    Maurizio Colecchia
    Biagio Paolini
    Giuseppe Pelosi
    Nicola Nicolai
    Giuseppe Procopio
    Roberto Salvioni
    Filippo G. De Braud
    Investigational New Drugs, 2016, 34 : 236 - 242
  • [8] Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Bai, Xue
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Xu, Jiahui
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
    Necchi, Andrea
    Lo Vullo, Salvatore
    Mariani, Luigi
    Raggi, Daniele
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Crippa, Flavio
    Di Genova, Nicola
    Perrone, Federica
    Colecchia, Maurizio
    Paolini, Biagio
    Pelosi, Giuseppe
    Nicolai, Nicola
    Procopio, Giuseppe
    Salvioni, Roberto
    De Braud, Filippo G.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 236 - 242
  • [10] A multicenter, open-label, single-arm, phase IV study evaluating the safety of biosimilar bevacizumab in patients with solid tumors
    Narayanan, P.
    Upveja, K. H.
    Deodhar, S.
    Kapur, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1613 - S1613
12345